A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age

References

• Viboud C, Boëlle PY, Cauchemez S, Lavenu A, Valleron AJ, Flahault A, et al. Risk factors of influenza transmission in households. Br J Gen Pract 2004; 54:684 - 9; PMID: 15353055
   PubMed Web of Science ®Google Scholar
• Heikkinen T, Silvennoinen H, Peltola V, Ziegler T, Vainionpaa R, Vuorinen T, et al. Burden of influenza in children in the community. J Infect Dis 2004; 190:1369 - 73; http://dx.doi.org/10.1086/424527; PMID: 15378427
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000; 342:232 - 9; http://dx.doi.org/10.1056/NEJM200001273420402; PMID: 10648764
   PubMed Web of Science ®Google Scholar
• Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr., Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000; 342:225 - 31; http://dx.doi.org/10.1056/NEJM200001273420401; PMID: 10648763
   PubMed Web of Science ®Google Scholar
• Neuzil KM, Zhu Y, Griffin MR, Edwards KM, Thompson JM, Tollefson SJ, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002; 185:147 - 52; http://dx.doi.org/10.1086/338363; PMID: 11807687
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61:613 - 8; PMID: 22895385
   PubMedGoogle Scholar
• Mereckiene J, Cotter S, Nicoll A, Levy-Bruhl D, Ferro A, Tridente G, et al. National seasonal influenza vaccination survey in Europe, 2008. Euro Surveill 2008; 13:19017; PMID: 18947524
   PubMedGoogle Scholar
• Public Health Agency of Canada National Advisory Committee on Immunization. Statement on seasonal influenza vaccine for 2011-2012. 2011; 37 http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/11vol37/acs-dcc-5/ (Accessed 30 April 2013)
   Google Scholar
• Usonis V, Anca I, André F, Chlibek R, Ivaskeviciene I, Mangarov A, et al, Central European Vaccination Advisory Group. Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for influenza vaccination in children. BMC Infect Dis 2010; 10:168; http://dx.doi.org/10.1186/1471-2334-10-168; PMID: 20546586
   PubMed Web of Science ®Google Scholar
• Steinhoff MC. Influenza in young children: burden, immunisation, and policy. Lancet Infect Dis 2011; 11:2 - 3; http://dx.doi.org/10.1016/S1473-3099(10)70263-2; PMID: 21106444
   PubMed Web of Science ®Google Scholar
• UK Department of Health. Influenza. Green Book 2012; 19-v4_71 https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/147958/Green-Book-Chapter-19-v4_71.pdf (Accessed 30 April 2013)
   Google Scholar
• Wright PF, Dolin R, La Montagne JR. From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration. Summary of clinical trials of influenza vaccines--II. J Infect Dis 1976; 134:633 - 8; http://dx.doi.org/10.1093/infdis/134.6.633; PMID: 794423
   PubMed Web of Science ®Google Scholar
• Langley JM, Scheifele DW, Quach C, Vanderkooi OG, Ward B, McNeil S, et al. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. Vaccine 2012; 30:3389 - 94; http://dx.doi.org/10.1016/j.vaccine.2012.03.046; PMID: 22469860
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Hottes TS, Chong M, De Serres G, Scheifele DW, Ward BJ, et al. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics 2011; 128:e276 - 89; http://dx.doi.org/10.1542/peds.2010-2777; PMID: 21768314
   PubMed Web of Science ®Google Scholar
• FDA News Release. FDA approves seasonal influenza vaccine Fluarix for pediatric use; http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187156.htm (Accessed 30 April 2013)
   Google Scholar
• Treanor JJ, Campbell JD, Brady RC, Keitel WA, Drame M, Jain VK, et al. Rapid licensure of a new, inactivated influenza vaccine in the United States. Hum Vaccin 2005; 1:239 - 44; http://dx.doi.org/10.4161/hv.1.6.2376; PMID: 17012883
   PubMed Web of Science ®Google Scholar
• Baxter R, Jeanfreau R, Block SL, Blatter M, Pichichero M, Jain VK, et al. A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatr Infect Dis J 2010; 29:924 - 30; http://dx.doi.org/10.1097/INF.0b013e3181e075be; PMID: 20431425
   PubMed Web of Science ®Google Scholar
• Campbell JD, Chambers CV, Brady RC, Caldwell MC, Bennett NL, Fourneau MA, et al. Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine: a randomized study in US adults. Hum Vaccin 2011; 7:81 - 8; http://dx.doi.org/10.4161/hv.7.1.13553; PMID: 21285532
   PubMed Web of Science ®Google Scholar
• Frank AL, Webster RG, Glezen WP, Cate TR. Immunogenicity of influenza A/USSR (H1N1) subunit vaccine in unprimed young adults. J Med Virol 1981; 7:135 - 42; http://dx.doi.org/10.1002/jmv.1890070207; PMID: 7264612
   PubMed Web of Science ®Google Scholar
• Glezen WP, Kasel JA, Webster RG, Taber LH. Alternative approaches to immunization of children with inactivated influenza virus vaccines. J Infect Dis 1977; 136:Suppl S677 - 82; http://dx.doi.org/10.1093/infdis/136.Supplement_3.S677; PMID: 606791
   PubMedGoogle Scholar
• Webster RG, Glezen WP, Hannoun C, Laver WG. Potentiation of the immune response to influenza virus subunit vaccines. J Immunol 1977; 119:2073 - 7; PMID: 915292
   PubMed Web of Science ®Google Scholar
• Webster RG, Kasel JA, Couch RB, Laver WG. Influenza virus subunit vaccines. II. Immunogenicity and original antigenic sin in humans. J Infect Dis 1976; 134:48 - 58; http://dx.doi.org/10.1093/infdis/134.1.48; PMID: 59787
   PubMed Web of Science ®Google Scholar
• Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008; 16:CD004879
   Google Scholar
• Langley JM, Vanderkooi OG, Garfield HA, Hebert J, Chandrasekaran V, Jain VK, et al. Immunogenicity and Safety of 2 Dose Levels of a Thimerosal-Free Trivalent Seasonal Influenza Vaccine in Children Aged 6-35 Months: A Randomized, Controlled Trial. J Pediatric Infect Dis Soc 2012; 1:55 - 63; http://dx.doi.org/10.1093/jpids/pis012; PMID: 23687572
   PubMedGoogle Scholar
• Esposito S, Marchisio P, Montinaro V, Bianchini S, Weverling GJ, Pariani E, et al. The immunogenicity and safety of a single 0.5 mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥6 to <36 months: data from a randomized, Phase III study. Vaccine 2012; 30:7005 - 12; http://dx.doi.org/10.1016/j.vaccine.2012.09.069; PMID: 23059357
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011; 204:1879 - 85; http://dx.doi.org/10.1093/infdis/jir661; PMID: 21998477
   PubMed Web of Science ®Google Scholar
• Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70:767 - 77; http://dx.doi.org/10.1017/S0022172400022610; PMID: 4509641
   PubMedGoogle Scholar
• Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 2010; 10:18; http://dx.doi.org/10.1186/1471-2288-10-18; PMID: 20210985
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of influenza vaccines. Vaccine 2008; 26:Suppl 4 D41 - 4; http://dx.doi.org/10.1016/j.vaccine.2008.07.043; PMID: 19230158
   PubMed Web of Science ®Google Scholar
• Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011; 30:1081 - 5; http://dx.doi.org/10.1097/INF.0b013e3182367662; PMID: 21983214
   PubMed Web of Science ®Google Scholar
• Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi T, et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 2012; 31:745 - 51; http://dx.doi.org/10.1097/INF.0b013e31825687b0; PMID: 22466322
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves first quadrivalent vaccine to prevent seasonal influenza. February 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm294057.htm (Accessed 30 April 2013)
   Google Scholar
• Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013; 207:1878 - 87; http://dx.doi.org/10.1093/infdis/jit091; PMID: 23470848
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services FaDA. Approval Letter- Fluarix Quadrivalent. December 14, 2012http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm332484.htm (Accessed 30 April 2013)
   Google Scholar
• Hehme NW, Künzel W, Petschke F, Türk G, Raderecht C, van Hoecke C, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Investig 2002; 22:751 - 69; http://dx.doi.org/10.2165/00044011-200222110-00004
   Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for industry. Clinical data needed to support the licensure of seasonal inactivated influenza vaccines 30th April 2009. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm (Accessed 30 April 2013)
   Google Scholar